CytoDyn Provides Update on Phase 2 Clinical Trial with PRO 140 in GvHD
Patient enrollment proceeding under amended protocol
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company developing new antibody therapies for combating human immuno...
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.